The Relationship Between Bevacizumab Treatment and Platelet, Mean Platelet Volume and Thromboembolic Events in Patients with Metastatic Colorectal Cancer

Abstract

Objectives: Colorectal cancer (CRC), is one of the leading causes of mortality worldwide and is the second most commoncancer in developed countries. Bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelialgrowth factor has been approved for use in combination chemotherapy for the first or second-line treatment ofpatients with metastatic colorectal cancer. The risk of arterial thromboembolism was found to be higher in the patientsreceived combination treatment with bevacizumab. Mean platelet volume is a parameter that measures the plateletsize and is defined as a marker of platelet reactivity.Methods: A total of 108 patients from medical oncology department of Acibadem Kayseri Hospital with metastaticcolorectal cancer and receiving first line combination treatment with bevacizumab were included in this study. Age, gender,comorbidity status, body mass index, smoking status and the type of chemotherapy combination were also enrolled.Results: At the 3rd month of the treatment, mean platelet volume levels were found to be increased in the total patientgroup from 8.98±0.16 to 9.28±0.14 and this was statistically significant (p